Immunotherapy in Management of Endometrial Cancer

This online course is a highlight from the 2021 live virtual symposium which was hosted by the Miami Cancer Institute on Women’s Cancer which brought together a distinguished faculty for to focus on the medical management of common and important challenges facing health-care professionals who care for women with cancer.

Learn more about the Womens’ Cancer Symposium here.

Target Audience

Breast Surgeons, General Surgeons, Reconstructive Surgeons, Obstetricians and Gynecologists, Oncologists, Medical Oncologists, Physiatrist, Radiation Oncologists, Pathologists, Geneticists, Radiologists, General Practitioners and all other interested healthcare professionals.

Learning Objectives

  • Review existing data to support use of immunotherapy in endometrial cancer.
  • Discuss ongoing trials including immunotherapy for the care of women with endometrial cancer.
  • Apply relevant testing strategies to guide choice of immunotherapy in endometrial cancer.
  • Discuss adverse event management of immunotherapy.
Additional information
Bibliography: 
  • Sokol, E. S., Pavlick, D., Khiabanian, H., Frampton, G. M., Ross, J. S., Gregg, J. P., ... & Chung, J. H. (2020). Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO precision oncology, 4, 442-465.
  • Molina, J. M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., ... & Delfraissy, J. F. (2015). On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med, 373, 2237-2246.
  • Ott, P. A., Elez, E., Hiret, S., Kim, D. W., Morosky, A., Saraf, S., ... & Mehnert, J. M. (2017). Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J clin oncol, 35(34), 3823-3829.
  • Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., ... & Postel-Vinay, S. (2019). PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer. The Journal of clinical investigation, 129(3), 1211-1228.
  • Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., ... & Diaz Jr, L. A. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38(1), 1-10.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Course opens: 
06/01/2021
Course expires: 
04/30/2024

Shannon N. Westin, M.D., MPH
Associate Professor
Director, Early Drug Development and Phase 1 Trials
Department of Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center, 
Houston, Texas 

Shannon N. Westin, M.D., MPH, has indicated that she receives grant/research support from AstraZeneca, Clovis Oncology, Roche/Genentech, GSK/Tesaro, Novartis, Bayer, ArQule, Bio-Path, Cotinga Pharmaceuticals. She is also a consultant for Merck, Pfizer, Eisai, Zentalis, Agenus, and Circulogene. Her presentation will include discussion of off-label or unapproved usage.

Symposium Directors:
John P. Diaz, M.D., has indicated that he is a member of the speakers’ bureau for AstraZeneca and Merck. 

Gladys L. Giron, M.D., has indicated that her spouse is a consultant for Stryker. 

Nicholas C. Lambrou, M.D., has indicated that he is a consultant for Intuitive, Ethicon and Johnson & Johnson. 

Starr K. Mautner, M.D., has indicated that she does not have any relevant relationships with ineligible companies* to disclose. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*. 

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 0.AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Please login or register to take this course.

Required Hardware/software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.